已经提出了几种方法用于在总体人群和预定义亚组中进行测试，重点是控制 $FWER$ $\alpha$。

序贯测试（sequential tests）的拒绝区域基于 $(Z-, Z+)$（标准化检验统计量）进行说明。在所有测试中，$FWER$ 为 $\alpha = 0.025$​​ 。箭头（$\Rightarrow$）显示每个方法中执行假设检验的顺序。 $\alpha_1$表示分配给第一次测试的 $\alpha$，$\alpha_{O}$ 表示分配给整个测试的 $\alpha$。

# Parallel Subgroup Specific (Freidlin et. al. 2010)

One approach is to test specific subgroups with Bonferroni correction on $\alpha$ (parallel subgroupspecific design, Freidlin et al. 2010, 2013). This approach when strong belief exists that the positive group will benefit from the treatment more than the negative group.
该方法通过对 $\alpha$ 进行 $Bonferroni$ 校正来检验特定亚组。当人们坚信 $M_{+}$ 亚组会比 $M_{-}$ 亚组从治疗中受益更多时，就会采用这种方法。

![[./fig/Fig 2.1.1.png]]

# Sequential Subgroup Specific (Douilard et. al 2010)

One can also carry out the test in a sequential manner that provides more design efficiency (Douillard et al. 2010) where the positive group is tested at the level of $\alpha$ and, if the test is significant, the negative group is tested also at the level of $\alpha$.
还可以以顺序方式进行测试，以提供更高的设计效率（Douillard et al. 2010），其中 $M_{+}$ 亚组在 $\alpha$ 水平上进行检验，如果检验显著， $M_{-}$ 亚组也在 $\alpha$ 水平上进行测试。

![[./fig/Fig 2.1.2.png]]

# Fallback Procedure (Simon 2008)

Other strategies include testing the treatment effect in the overall patient population followed by testing in the marker positive group. This strategy offers the opportunity for sponsor to claim efficacy in a patient population as large as possible and is effective when treatment is also beneficial for the marker-negative group, although the treatment effect can be much smaller. A well-known example is the fallback procedure (Simon 2008).
（序贯测试的）其他策略包括先检验总体人群的治疗效果，然后在 $M_{+}$ 亚组中进行测试。该策略为（药物开发）赞助者提供了在尽可能大的患者群体中主张疗效的机会，并且当治疗对 $M_{-}$ 亚组也有益时是有效的，尽管治疗效果可能要小得多。

A well-known example is the fallback procedure (Simon 2008):the treatment effect is tested in the overall population at a reduced level of $\alpha_0$ ; if significant, the procedure stops and an overall effect is claimed; otherwise, the treatment effect is tested in the marker-positive group at $\alpha_{+}$ for claiming efficacy in a sub-population, where $\alpha_{0} + \alpha_{+} = \alpha$. 
一个众所周知的例子是Fallback Procedure（Simon 2008）：在总体人群中以降低的 $\alpha_0$ 水平检验治疗效果；如果显著，则停止程序并主张在总体人群有治疗效果；否则，在 $M_{+}$ 组中以 $\alpha_{+}$ 测试治疗效果，以主张在该亚组中有效，其中 $\alpha_{0} + \alpha_{+} = \alpha$。

![[./fig/Fig 2.1.4.png]]

# Two-Stage Test (Song and Chi 2007)

Song and Chi (2007) proposed an approach that takes into account the correlations between the test statistics derived from the overall population and the subgroup. They define a conservative threshold $\alpha_{0}$ and relaxed threshold $\alpha^{*}_{0}$ for the overall p-value, where $\alpha_{0} \lt \alpha \lt \alpha^{*}_0$.  If the overall p-value is less than $\alpha_{0}$ , the treatment effect is considered significant in the overall population and tested in the marker-positive group at level $\alpha$ ; if the overall p-value falls between $\alpha_{0}$ and $\alpha^{*}_{0}$ , the treatment effect in the overall population is borderline and to be tested in the marker-positive group at a more stringent level of $\alpha_{+}$ ($\alpha_{+} \lt \alpha$). If this test is significant, one goes back to test the overall treatment effect at level $\alpha$, where $\alpha_{+}$ is selected conditional on the value of the overall test statistics to control for the $FWER$.
Song 和 Chi (2007) 提出了一种方法，该方法考虑了从总体人群和亚组中得出的检验统计量之间的相关性。他们为总体 p 值定义了保守阈值 $\alpha_{0}$ 和宽松阈值 $\alpha^{*}_{0}$ ，其中 $\alpha_{0} \lt \alpha \lt \alpha^{*}_0$ 。
1. 如果总体 $p$ 值小于 $\alpha_{0}$，则认为治疗效果在总体人群中显着，并在 $M_{+}$ 亚组中的 $\alpha$ 水平进行检验；
2. 如果总体 $p$ 值落在 $\alpha_{0}$ 和 $\alpha^{*}_{0}$ 之间，则总体人群中的治疗效果处于临界状态，需要在 $M_{+}$ 亚组中以更严格的 $\alpha_{+}$ 水平（$\alpha_{+} \lt \alpha$）进行测试。
3. 如果该检验显著，则返回到 $\alpha$ 水平检验总体治疗效果，其中选择 $\alpha_{+}$ 的条件是根据总体检验统计数据的值来控制 $FWER$。
注意：这里提到的总体 $p$ 值、总体检验实质上是指先前的总体人群 $H_{0O}$ 和 $H_{A0}$ 的假设检验。

![[./fig/Fig 2.1.6.png]]